
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is a precision medicine company that is positioning itself for strong growth with the acquisition of Naveris, higher revenue and test volume, a final transplant LCD decision expected soon, and a shift towards a higher-margin MRD business. They are also expanding into the hematology/oncology market with a new product and have divested their lab products business to focus on their core business and increase profits. Despite potential industry challenges, CDNA remains optimistic about its future growth potential with a strong market share in the transplant market and investments in new initiatives and sales force expansion.
Bears say
CareDx is facing potential LCD negative revenue and earnings impacts in the near term as a result of proposed limits on molecular testing and uncertainty surrounding the final outcome of the LCD. Additionally, the company is heavily relying on inorganic growth through acquisitions, which may have an impact on its stock price. Furthermore, there may be challenges in adoption from clinicians and healthcare administrators due to the risks and uncertainties surrounding liability and reimbursement.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares